Nippon Genetics Europe

nippongenetics.eu

Nippon Genetics Europe is the European subsidiary of Nippon genetics Co. Ltd. in Japan. We are focused on the manufacturing, sales and marketing of products for the Life Science community. The Japanese company was founded in 1988 in Tokyo and Kyoto, whereas the German office started on January 2005 Our customers are scientists working at universities and research institutes, pharmaceutical and biotech companies and/or clinical labs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

news image

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More

MedTech

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

news image

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

news image

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

news image

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More
news image

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More
news image

MedTech

COSMOSID LAUNCHES ACCURATE AND EASY FUNCTIONAL MICROBIOME ANALYSIS WITH NEW SOFTWARE PLATFORM, COSMOSID-HUB: MICROBIOME

CosmosID | September 27, 2021

A complete analysis of the microbiome should combine taxonomic profiling ("who is there?") with functional characterization ("what are they doing?") to discover the capabilities of an entire community of microorganisms. But research teams often require specialized training and extensive computational infrastructure to establish an in-house suite of tools for processing shotgun metagenomic data – and even with the right know-how, the processing can be both time-consuming...

Read More
news image

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More
news image

BIOMICA ANNOUNCES THE ADVANCEMENT TO LARGE-SCALE PRODUCTION OF BMC128, ITS LIVE BACTERIAL PRODUCT CANDIDATE CONSORTIUM

Biomica | October 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology program, anticipated to begin in 2021. BMC128 is advan...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us